Effects of exogenous glucose on mycorrhizal colonization in vitro by early-stage and late-stage ectomycorrhizal fungi

1995 ◽  
Vol 73 (6) ◽  
pp. 898-904 ◽  
Author(s):  
Leonard J. Hutchison ◽  
Yves Piché

Under aseptic conditions, seedlings of 12 common tree species found in eastern Canada (Alnus rugosa, Betula papyrifera, Betula alleghaniensis, Abies balsamea, Tsuga Canadensis, Pinus strobes, Pinus resinosa, Pinus banksiana, Larix laricina, Picea glauca, Picea mariana, and Picea rubens) were inoculated with 10 species of ectomycorrhizal fungi (Piloderma bicolour, Lactarius thyinos, Lactarius subpurpureus, Lactarius torminosus, Hebeloma longicaudum, Cenococcum geophilum, Suillus sinuspaulianus, Suillus tomentosus, Leccinum holopus, and Boletinus paluster) in the absence or presence of exogenous glucose (2 g/L). Early-stage ectomycorrhizal colonizers with a broad host range (e.g., H. longicaudum) appeared to be less dependent upon the exogenous carbohydrate supply for successful formation of ectomycorrhizae than were host-specific late-stage ectomycorrhizal colonizers (e.g., Lactarius subpurpureus). Further investigations revealed, however, that while levels of exogenous glucose (1.0 and 10.0 g/L) increased mycelial growth of late-stage ectomycorrhizal colonizers, a detrimental effect on the growth of the seedlings took place in the presence of these fungi, rather than a concurrent increase in colonization and infection of the host roots. It is suggested that secondary fungal metabolites toxic to the plants are released as a consequence of increased mycelial growth in response to an increase in glucose concentrations. Thus, when dealing with late-stage ectomycorrhizal colonizers and host plants in mycorrhizal synthesis experiments, the exogenous glucose concentration is critical. Key words: early-stage fungi, late-stage fungi, ectomycorrhizae, glucose, root colonization, fungal metabolites.

Botany ◽  
2016 ◽  
Vol 94 (5) ◽  
pp. 347-357
Author(s):  
Rodney Arthur Savidge

Rims of bordered pits form on the primary walls of radially enlarged cambial derivatives prior to the onset of general secondary-wall formation. A recent report (Botany, 2014, 92(7): 495–511) raised the possibility that the chemical composition of the rim might be different from that of the secondary wall. To investigate this, early-stage nonfluorescent and late-stage autofluorescent rims were separated from cambial derivatives of Abies balsamea (L.) Mill. and purified to homogeneity by density-gradient centrifugation. Solid state nuclear magnetic resonance spectroscopy, Raman microspectroscopy, combined gas chromatography – mass spectroscopy, enzyme digestion, and chemical resilience data support the interpretation that cellulose alone is the microfibrillar polysaccharide of nonfluorescent early-stage rims. A lignin is additionally present in late-stage rims, and it evidently bonds with cellulose because rims are extraordinarily resistant to hydrolysis by either enzymes or strong acid.


1987 ◽  
Vol 65 (5) ◽  
pp. 869-875 ◽  
Author(s):  
Michael L. Cline ◽  
Raymond C. France ◽  
C. P. Patrick Reid

Geographically distinct isolates of the ectomycorrhizal fungi Pisolithus tinctorius, Cenococcum geophilum, Thelephora terrestris, and Suillus granulatus showed definite temperature optima for growth in pure culture. Temperatures promoting the greatest fungal growth varied interspecifically and intraspecifically over the temperature treatments of 16, 21, 27, 32, and 38 °C. Of the four fungal species, Pisolithus tinctorius exhibited the greatest growth at the higher temperature treatments, with growth optima for all isolates occurring between 21 and 32 °C. The maximum temperature for growth of Cenococcum geophilum was 27 °C, with optimal mycelial growth occurring between 16 and 27 °C, depending upon the particular isolate considered. Suillus granulatus showed greatest mycelial growth at 27 °C and below, with temperature optima for the different isolates ranging from 16 to 32 °C. The pure-culture growth of Thelephora terrestris was high relative to the other fungal species examined with growth optima between 21 and 27 °C. The degree of intraspecific variation of mycelial growth in response to temperature was high for all fungal species, indicating the existence of physiologically distinct genotypes. Attempts to relate fungal growth performance to geographic origin of isolate showed a trend for Pisolithus tinctorius. However, no such relationships were apparent for the other species.


2021 ◽  
pp. 073112142110286
Author(s):  
Alexander B. Kinney ◽  
Nicholas J. Rowland

This is an article that draws on the institutional work literature about provisional institutions. To date, nearly every U.S. sector has been impacted by COVID-19. To sustain their core missions, highly institutionalized organizations such as universities have had to rethink foundational structures and policies. Using a historical ethnographic approach to investigate records from faculty senate deliberations at “Rural State University” (RSU), the authors examine the implementation of a temporary grading policy to supplement traditional, qualitative grades spring 2020 during the outbreak. The authors find that RSU implemented a temporary, supplemental grading policy as a provisional institution to momentarily supersede traditional grading as a means to—as soon as possible—return to it. This finding contrasts with the common understanding that provisional institutions operate primarily as a temporary solution to a social problem that leads to more stable and enduring, ostensibly nonprovisional institutions. The temporary grading policy, the authors argue, constitutes a “late-stage” provisional institution and, with this new lens, subsequently characterize the more commonplace understanding of provisional institutions as “early-stage.” This contribution has theoretical implications for studies of institutions and empirical implications for research on shared governance and disruption in higher education.


2021 ◽  
pp. 003335492199917
Author(s):  
Lindsey A. Jones ◽  
Katherine C. Brewer ◽  
Leslie R. Carnahan ◽  
Jennifer A. Parsons ◽  
Blase N. Polite ◽  
...  

Objective For colon cancer patients, one goal of health insurance is to improve access to screening that leads to early detection, early-stage diagnosis, and polyp removal, all of which results in easier treatment and better outcomes. We examined associations among health insurance status, mode of detection (screen detection vs symptomatic presentation), and stage at diagnosis (early vs late) in a diverse sample of patients recently diagnosed with colon cancer from the Chicago metropolitan area. Methods Data came from the Colon Cancer Patterns of Care in Chicago study of racial and socioeconomic disparities in colon cancer screening, diagnosis, and care. We collected data from the medical records of non-Hispanic Black and non-Hispanic White patients aged ≥50 and diagnosed with colon cancer from October 2010 through January 2014 (N = 348). We used logistic regression with marginal standardization to model associations between health insurance status and study outcomes. Results After adjusting for age, race, sex, and socioeconomic status, being continuously insured 5 years before diagnosis and through diagnosis was associated with a 20 (95% CI, 8-33) percentage-point increase in prevalence of screen detection. Screen detection in turn was associated with a 15 (95% CI, 3-27) percentage-point increase in early-stage diagnosis; however, nearly half (47%; n = 54) of the 114 screen-detected patients were still diagnosed at late stage (stage 3 or 4). Health insurance status was not associated with earlier stage at diagnosis. Conclusions For health insurance to effectively shift stage at diagnosis, stronger associations are needed between health insurance and screening-related detection; between screening-related detection and early stage at diagnosis; or both. Findings also highlight the need to better understand factors contributing to late-stage colon cancer diagnosis despite screen detection.


Author(s):  
L. Schmidt ◽  
O. Sehic ◽  
C. Wild

Abstract Background We considered the extent of the contribution of publicly funded research to the late-stage clinical development of pharmaceuticals and medicinal products, based on the European Commission (EC) FP7 research funding programme. Using two EC FP7-HEALTH case study examples—representing two types of outcomes—we then estimated wider public and charitable research funding contributions. Methods Using the publicly available database of FP7-HEALTH funded projects, we identified awards relating to late-stage clinical development according to the systematic application of inclusion and exclusion criteria, classified them according to product type and clinical indication, and calculated total EC funding amounts. We then identified two case studies representing extreme outcomes: failure to proceed with the product (hepatitis C vaccine) and successful market authorisation (Orfadin® for alkaptonuria). Total public and philanthropic research funding contributions to these products were then estimated using publicly available information on funding. Results 12.3% (120/977) of all EC FP7-HEALTH awards related to the funding of late-stage clinical research, totalling € 686,871,399. Pharmaceutical products and vaccines together accounted for 84% of these late-stage clinical development research awards and 70% of its funding. The hepatitis C vaccine received total European Community (FP7 and its predecessor, EC Framework VI) funding of €13,183,813; total public and charitable research funding for this product development was estimated at € 77,060,102. The industry sponsor does not consider further development of this product viable; this now represents public risk investment. FP7 funding for the late-stage development of Orfadin® for alkaptonuria was so important that the trials it funded formed the basis for market authorisation, but it is not clear whether the price of the treatment (over €20,000 per patient per year) adequately reflects the substantial public funding contribution. Conclusions Public and charitable research funding plays an essential role, not just in early stage basic research, but also in the late-stage clinical development of products prior to market authorisation. In addition, it provides risk capital for failed products. Within this context, we consider further discussions about a public return on investment and its reflection in pricing policies and decisions justified.


Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 3975
Author(s):  
Marco A. De Velasco ◽  
Yurie Kura ◽  
Naomi Ando ◽  
Noriko Sako ◽  
Eri Banno ◽  
...  

Significant improvements with apalutamide, a nonsteroidal antiandrogen used to treat patients suffering from advanced prostate cancer (PCa), have prompted evaluation for additional indications and therapeutic development with other agents; however, persistent androgen receptor (AR) signaling remains problematic. We used autochthonous mouse models of Pten-deficient PCa to examine the context-specific antitumor activity of apalutamide and profile its molecular responses. Overall, apalutamide showed potent antitumor activity in both early-stage and late-stage models of castration-naïve prostate cancer (CNPC). Molecular profiling by Western blot and immunohistochemistry associated persistent surviving cancer cells with upregulated AKT signaling. While apalutamide was ineffective in an early-stage model of castration-resistant prostate cancer (CRPC), it tended to prolong survival in late-stage CRPC. Molecular features associated with surviving cancer cells in CRPC included upregulated aberrant-AR, and phosphorylated S6 and proline-rich Akt substrate of 40 kDa (PRAS40). Strong synergy was observed with the pan-AKT inhibitor GSK690693 and apalutamide in vitro against the CNPC- and CRPC-derived cell lines and tended to improve the antitumor responses in CNPC but not CRPC in vivo. Upregulation of signal transducer and activator of transcription 3 (STAT3) and proviral insertion in murine-1 (PIM-1) were associated with combined apalutamide/GSK690693. Our findings show that apalutamide can attenuate Pten-deficient PCa in a context-specific manner and provides data that can be used to further study and, possibly, develop additional combinations with apalutamide.


2021 ◽  
Vol 28 (3) ◽  
pp. 1946-1956
Author(s):  
Aisha K. Lofters ◽  
Evgenia Gatov ◽  
Hong Lu ◽  
Nancy N. Baxter ◽  
Sara J. T. Guilcher ◽  
...  

Lung cancer is the most common cancer and cause of cancer death in Canada, with approximately 50% of cases diagnosed at stage IV. Sociodemographic inequalities in lung cancer diagnosis have been documented, but it is not known if inequalities exist with respect to immigration status. We used multiple linked health-administrative databases to create a cohort of Ontarians 40–105 years of age who were diagnosed with an incident lung cancer between 1 April 2012 and 31 March 2017. We used modified Poisson regression with robust standard errors to examine the risk of diagnosis at late vs. early stage among immigrants compared to long-term residents. The fully adjusted model included age, sex, neighborhood-area income quintile, number of Aggregated Diagnosis Group (ADG) comorbidities, cancer type, number of prior primary care visits, and continuity of care. Approximately 62% of 38,788 people with an incident lung cancer from 2012 to 2017 were diagnosed at a late stage. Immigrants to the province were no more likely to have a late-stage diagnosis than long-term residents (63.5% vs. 62.0%, relative risk (RR): 1.01 (95% confidence interval (CI): 0.99–1.04), adjusted relative risk (ARR): 1.02 (95% CI: 0.99–1.05)). However, in fully adjusted models, people with more comorbidities were less likely to have a late-stage diagnosis (adjusted relative risk (ARR): 0.82 (95% CI: 0.80–0.84) for those with 10+ vs. 0–5 ADGs). Compared to adenocarcinoma, small cell carcinoma was more likely to be diagnosed at a late stage (ARR: 1.29; 95% CI: 1.27–1.31), and squamous cell (ARR: 0.89; 95% CI: 0.87–0.91) and other lung cancers (ARR: 0.93; 95% CI: 0.91–0.94) were more likely to be diagnosed at an early stage. Men were also slightly more likely to have late-stage diagnosis in the fully adjusted model (ARR: 1.08; 95% CI: 1.05–1.08). Lung cancer in Ontario is a high-fatality cancer that is frequently diagnosed at a late stage. Having fewer comorbidities and being diagnosed with small cell carcinoma was associated with a late-stage diagnosis. The former group may have less health system contact, and the latter group has the lung cancer type most closely associated with smoking. As lung cancer screening programs start to be implemented across Canada, targeted outreach to men and to smokers, increasing awareness about screening, and connecting every Canadian with primary care should be system priorities.


1997 ◽  
Vol 481 ◽  
Author(s):  
Celeste Sagui ◽  
Dean Stinson O'Gorman ◽  
Martin Grant

ABSTRACTIn this work we have re-examined the classical problem of nucleation and growth. A new model considers the correlations among droplets and naturally incorporates the crossover from the early-stage, nucleation dominated regime to the scaling, late-stage, coarsening regime within a single framework.


1996 ◽  
Vol 46 (1) ◽  
pp. 19-26 ◽  
Author(s):  
B. Brandon Curry ◽  
Milan J. Pavich

A10Be inventory and14C ages of material from a core from northernmost Illinois support previous interpretations that this area was ice free from ca. 155,000 to 25,000 yr ago. During much of this period, from about 155,000 to 55,000 yr ago, 10Be accumulated in the argillic horizon of the Sangamon Geosol. Wisconsinan loess, containing inherited 10Be, was deposited above the Sangamon Geosol from ca. 55,000 to 25,000 yr ago and was subsequently buried by late Wisconsinan till deposited by the Lake Michigan Lobe of the Laurentide Ice Sheet. The Sangamonian interglacial stage has been correlated narrowly to marine oxygen isotope substage 5e; our data indicate instead that the Sangamon Geosol developed during late stage 6, all of stages 5 and 4, and early stage 3.


1998 ◽  
Vol 111 (16) ◽  
pp. 2315-2327 ◽  
Author(s):  
B.J. Cha ◽  
B. Error ◽  
D.L. Gard

We used affinity-purified polyclonal antibodies to characterize the distribution and function of XMAP230, a heat-stable microtubule-associated protein isolated from Xenopus eggs, during oogenesis. Immunoblots revealed that XMAP230 was present throughout oogenesis and early development, but was most abundant in late stage oocytes, eggs, and early embryos. Immunofluorescence microscopy revealed that XMAP230 was associated with microtubules in oogonia, post-mitotic stage 0 oocytes, early stage I oocytes, and during stage IV-VI of oogenesis. However, staining of microtubules by anti-XMAP230 was not detectable during late stage I through stage III. In stage VI oocytes, anti-XMAP230 stained a large subset of microtubules that were also stained with monoclonal antibodies specific for acetylated (α)-tubulin. During oocyte maturation, XMAP230 was associated with the transient microtubule array that serves as the precursor of the first meiotic spindle, as well as both first and second meiotic spindles. The extensive array of cytoplasmic microtubules present throughout maturation was not detectably stained by anti-XMAP230. Microinjection of anti-XMAP230 locally disrupted the organization and acetylation of microtubules in stage VI oocytes, and reduced the re-acetylation of microtubules during recovery from cold-induced microtubule disassembly. Subsequent maturation of oocytes injected with anti-XMAP230 resulted in defects in the assembly of the transient microtubules array and first meiotic spindle. These observations suggest that XMAP230 is required for the stabilization and organization of cytoplasmic and spindle microtubules in Xenopus oocytes and eggs.


Sign in / Sign up

Export Citation Format

Share Document